How I treat recurrent deep-vein thrombosis by Paul A. Kyrle Blood Volume 127(6):696-702 February 11, 2016 ©2016 by American Society of Hematology.

Slides:

Advertisements

Similar presentations

Evidence-Based Management of Anticoagulant Therapy

Advertisements

PE & DVT treatment. Classification of Emboli - Fat and Marrow ◦Sequelae from any marrow/adipose injury ◦fat and cells are released into bloodstream ◦CPR,

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

Antithrombotic Therapy for Venous Thromboembolic Diseases

Stroke prevention in atrial fibrillation

Protein C and Protein S Deficiency Paolo Aquino 18 February 2003.

CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.

Venous thromboembolism: how long to treat?

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

Unprovoked DVT in a young patient

Neue Antikoagulantien bei spontaner und Tumor-assoziierter VTE Paul Kyrle Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien.

Vanderbilt Pediatric Hematology Anticoagulation Guidance Protocol Robert F. Sidonio, Jr. MD, MSc. 4/12/12 Warfarin Monitoring If inpatient, consider monitoring.

Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

Venous Thromboembolism

DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?

H.R. Buller, G. Agnelli Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva,

Dodson Thompson, DO Northlakes Community Clinic Minong, WI.

71-year old male Admitted with worsening shortness of breath PMHx: Severe COPD, A.Fib, CHF/ischemic, PE On long term anticoagulation with Pradaxa 150.

Pulmonary Embolism Pulmonary embolism is blockage in one or more arteries in your lungs. Maggie Trainor.

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.

Diagnosis of Deep Vein Thrombosis Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis, 9th.

Antithrombotic Therapy for VTE: CHEST Guidelines 2016

Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,

Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe −/− mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Warfarin PSD/HOF001/GB/DC/Rev013 Issued : Review interval:12 months This document may be reviewed and reissued electronically without notice.

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.

Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.

Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.

Outpatient DVT assessment & treatment Daniel Gilada.

Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients Thrombosis Research (2008)

TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

Evidence-Based Management of Anticoagulant Therapy

By: Dr. Nalaka Gunawansa

The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,

Treatment and Prevention of Heparin-Induced Thrombocytopenia

Anticoagulants in the Treatment of Venous Thromboembolism

Ortho Warfarin Dosing Protocol

Prevention of Venous Thromboembolism in Orthopedic Surgery Patients

Hydroxyurea makes inflammation “just right”?

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Use of new oral anticoagulants in retinal trombosis and ischemic optic neuritis secondary to Anti Phospholipid Syndrome (APS). Patricia Fanlo Mateo1,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy by Chun.

Catheter-related deep venous thrombosis in children with hemophilia

Timing the First Postoperative Dose of Anticoagulants

Owen N. Johnson, MD, David L

New Oral Anticoagulants and VTE Management

Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis Paloma López-Beret, MD, Antonio Orgaz, MD,

by Sabah Sallah, and Jim Y. Wan

Timing the First Postoperative Dose of Anticoagulants

Cancer-Associated Thrombosis

by Alex C. Spyropoulos, and James D. Douketis

How I treat cancer-associated venous thromboembolism

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Bv+Bs regimen schedule.

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Overcoming “aspirin resistance” in MPN

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI by Naranie Shanmuganathan, Susan.

Algorithm of endovascular therapeutic strategies for tandem occlusions

Suggested procedure to diagnose recurrent DVT

Study protocol. Study protocol. All participants were studied on four occasions: Twice before and twice after an 8-wk treatment period on low-dosage, low.

Presentation transcript:

How I treat recurrent deep-vein thrombosis by Paul A. Kyrle Blood Volume 127(6): February 11, 2016 ©2016 by American Society of Hematology

Suggested procedure to diagnose recurrent DVT. aNoncompressibility of a previously affected vein segment or noncompressibility of any vein segment in the ipsilateral leg in the absence of a previous CUS result; balternative imaging techniques include venogr... Paul A. Kyrle Blood 2016;127: ©2016 by American Society of Hematology

Suggested treatment protocol for recurrent DVT. aApixaban 10 mg twice daily for 1 week followed by 5 mg twice daily, reduce dose to 2.5 mg twice daily after 6 months; rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily; LMWH once or twice... Paul A. Kyrle Blood 2016;127: ©2016 by American Society of Hematology

Suggested treatment protocol for recurrent DVT during anticoagulant treatment. aLMWH once or twice daily at therapeutic dose together with a VKA (target INR, ) and continue LMWH until a stable INR has been reached, but for a minimum of 5 days; bapixa... Paul A. Kyrle Blood 2016;127: ©2016 by American Society of Hematology